24 stories found
Merck reported first-quarter earnings that surpassed Wall Street estimates, driven by robust demand for its oncology drug Keytruda and other new products. The pharmaceutical giant also narrowed its full-year outlook, factoring in a significant charge related to a recent deal.
Pfizer and Astellas have received FDA priority review for their bladder cancer treatment, Padcev, when used in combination with Merck's Keytruda, signaling a potential expedited approval process for the therapy.
Seven Indian pharmaceutical firms are reportedly in the race to develop a more affordable version of the drug Keytruda, with experts anticipating its availability within two years.
Pharmaceutical giant Merck is undergoing a transformation driven by strategic acquisitions as it prepares for the upcoming patent expiration of its top-selling cancer drug, Keytruda.
Concerns are rising in India over the cancer drug Keytruda's availability, high cost, and reports of leaks and fake versions. Merck & Co has stated that healthcare facilities are responsible for the used packaging of the drug.
Merck has announced a $6.7 billion deal to acquire a leukemia treatment, a strategic move as the company prepares for the upcoming expiration of exclusivity for its blockbuster cancer drug, Keytruda.
Merck's cancer drug Keytruda has demonstrated an overall survival benefit in patients with ovarian cancer, according to new findings.
Merck announced plans to divide its human health business into two separate divisions, separating its cancer franchise from non-oncology medicines, to mitigate the impact of Keytruda patent loss.
Merck & Co., Inc. (MRK) has been granted FDA Priority Review for its KEYTRUDA regimen in the treatment of muscle-invasive bladder cancer.
A global scam has been uncovered involving fraudsters exploiting the fear of cancer by selling fake versions of the well-known cancer drug Keytruda, highlighting a growing worldwide problem of fraudulent treatments.
Articles provide an overview of key concepts for the UPSC Prelims examination, including science topics like sports genomics, Kessler Syndrome, and designer rice, as well as governance issues, presented through daily quizzes and concept explanations.
An international team of journalists, including Direkt36, revealed that the American manufacturer of Keytruda maintains high prices and delays the market entry of cheaper alternatives for the revolutionary cancer drug.
Merck has finalized its acquisition of Terns Pharmaceuticals for nearly $6 billion, aiming to boost its cancer drug pipeline following promising clinical data on a bone and blood cancer treatment.
Deutsche Bank has upgraded Merck (MRK) to a 'Buy' rating, expressing optimism about the company's future beyond the patent expiration of its key drug, Keytruda.
Pharmaceutical companies Merck and Eisai have encountered a setback in a late-stage clinical trial for their Keytruda regimen, intended for the treatment of kidney cancer.
Hungarian Prime Minister Viktor Orbán has accepted full responsibility for his party's recent election defeat, stating he was surprised by the outcome. He indicated that a complete renewal is needed, suggesting a political era has ended.
Oncologists are suggesting smaller doses of the cancer drug Keytruda to alleviate the financial burden on patients, a proposal that has been rejected by the drug's manufacturer.
A joint investigation by DW and ICIJ highlights how pricing and patent strategies have made Merck's Keytruda a top-selling drug while limiting access for many patients worldwide. The report uncovers a significant global divide in the availability of the life-saving medicine.
Keytruda, the world's highest-grossing drug, is reportedly the most expensive medication in Austria, raising questions about pharmaceutical company profits and the vulnerability of health systems.
Merck & Co. (MRK) is implementing measures to mitigate the impact of the upcoming loss of exclusivity for its drug KEYTRUDA.
Merck is restructuring its business by separating its oncology division from non-cancer drug operations, a move reportedly in preparation for the 2028 patent expiry of its blockbuster cancer treatment, Keytruda.
Merck & Co. saw its stock advance, driven by robust sales of its drug Keytruda and favorable results from recent clinical trials.